Supervised disulfiram treatment in a telemedicine setting - What impact does the loss of personal doctor-patient interaction have on the probability of relapse and patient compliance?

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023940

Enrollment

Registered

2024-01-10

Start date

2023-03-27

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F10

Interventions

Group 1: Alcohol-dependent patients in a telemedicine setting Group 2: Alcohol-dependent patients undergoing supervised administration of disulfiram

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: - Male and female subjects between 18 and 80 years old - Existing alcohol dependence - Indication for treatment with disulfiram - Ability to give consent after detailed written explanation (“Fully Informed Consent”) - Informed consent must be in writing (“Written Informed Consent”)

Exclusion criteria

Exclusion criteria: -Pregnancy -Desire to have children -lack of ability to consent -Contraindications to treatment with disulfiram

Design outcomes

Primary

Measure	Time frame
This clinical study in a cross-over design aims to compare the compliance and probability of relapse of patients under the condition of a telemedical disulfiram consultation using the Zenalyser with the compliance and probability of relapse of these patients under the condition of participation in the face-to-face consultation. The aim is to compare the patients' adherence and compliance and the number of relapses in the telemedicine setting with their adherence, compliance and number of relapses in the face-to-face consultation.	—

Measure

Time frame

This clinical study in a cross-over design aims to compare the compliance and probability of relapse of patients under the condition of a telemedical disulfiram consultation using the Zenalyser with the compliance and probability of relapse of these patients under the condition of participation in the face-to-face consultation. The aim is to compare the patients' adherence and compliance and the number of relapses in the telemedicine setting with their adherence, compliance and number of relapses in the face-to-face consultation.

—

Secondary

Measure	Time frame
Non-inferiority	—

Countries

Germany

Contacts

Public ContactAnne Koopmann

Zentralinstitut für Seelische Gesundheit

anne.koopmann@zi-mannheim.de62117033541

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026